Procaps Group S A Revenue Growth Rates (PROCF), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Procaps Group S a   (PROCF)
 

PROCF's Revenue Growth by Quarter and Year

Procaps Group S A 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PROCF Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 423.75
3rd Quarter September 0.00
2nd Quarter June 110.06
1st Quarter March 0.00
FY 533.81





PROCF Revenue fourth quarter 2023 Y/Y Growth Comment
Procaps Group S A showed record Revenue improvement in the fourth quarter 2023 with 3.37% from the fourth quarter 2023 2022, to $ 423.75 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 147 other companies have achieved higher Revenue growth. While Procaps Group S A ' s Revenue increase of 3.37% ranks overall at the positon no. 2181 in the fourth quarter 2023.


PROCF Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 3.37 % - - -
3rd Quarter September - - - -
2nd Quarter June -2.1 % - - -
1st Quarter March - - - -
FY   2.2 % - - -

Financial Statements
Procaps Group S A 's fourth quarter 2023 Revenue $ 423.75 millions PROCF's Income Statement
Procaps Group S A 's fourth quarter 2022 Revenue $ 409.92 millions Quarterly PROCF's Income Statement


PROCF Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   2.2 % - - -


Back to PROCF Growth rate Comparisons >> Back to PROCF Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #148
Healthcare Sector #409
Overall #2181

Revenue Y/Y Growth Statistics
High Average Low
3.37 % 0.64 % -2.1 %
 
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #148
Healthcare Sector #409
Overall #2181
Revenue Y/Y Growth Statistics
High Average Low
3.37 % 0.64 % -2.1 %
 

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Procaps Group S A 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PROCF's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PROCF's IV. Quarter Q/Q Revenue Comment


Procaps Group S A 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 373.80 $ 423.75 $ 403.20 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) -11.79 % 5.1 % -0.13 % - -
Year on Year Revenue Growth Overall Ranking # 2718 # 0 # # #
Seqeuential Revenue Change (TTM) -11.79 % 5.1 % -0.13 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 2718 # 0 # # #


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2024 Procaps Group S A reported a decline in Revenue by -11.79% year on year, to $374 millions, compare to the 5.1% growth at Dec 31 2023.

In the Healthcare sector 432 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2718.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 162
Healthcare Sector # 433
Overall # 2718

Revenue TTM Y/Y Growth Statistics
High Average Low
5.1 %
 -2.28 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 162
Sector # 433
S&P 500 # 2718
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2024 Procaps Group S A reported a decline in Revenue by -11.79% year on year, to $374 millions, compare to the 5.1% growth at Dec 31 2023.

In the Healthcare sector 432 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2718.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 162
Healthcare Sector # 433
Overall # 2718

Revenue TTM Y/Y Growth Statistics
High Average Low
5.1 %
-2.28 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 162
Sector # 433
S&P 500 # 2718




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PROCF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Dr Reddy s Laboratories Limited5.87%$ 5.874 millions
Merck and Co Inc 5.79%$ 5.792 millions
Vapotherm Inc 5.74%$ 5.739 millions
Elanco Animal Health Incorporated5.50%$ 5.505 millions
Pacira Biosciences inc 5.40%$ 5.402 millions
Royalty Pharma Plc5.36%$ 5.359 millions
Cano Health Inc 5.27%$ 5.271 millions
Alector Inc 5.19%$ 5.194 millions
Zai Lab Limited5.16%$ 5.160 millions
Ocular Therapeutix Inc 5.16%$ 5.158 millions
Tactile Systems Technology Inc 5.05%$ 5.046 millions
Ontrak Inc 5.02%$ 5.020 millions
Select Medical Holdings Corp4.89%$ 4.894 millions
Fulgent Genetics Inc 4.68%$ 4.679 millions
Fonar Corporation4.66%$ 4.659 millions
Fresenius Medical Care Ag4.45%$ 4.448 millions
Novocure Limited4.17%$ 4.170 millions
Jazz Pharmaceuticals Plc4.10%$ 4.095 millions
Surgery Partners Inc 4.00%$ 4.002 millions
Evotec Se3.99%$ 3.989 millions
Ligand Pharmaceuticals Incorporated3.90%$ 3.905 millions
Lifeloc Technologies Inc 3.78%$ 3.778 millions
Teladoc Health Inc 3.58%$ 3.578 millions
Iqvia Holdings Inc 3.45%$ 3.450 millions
Procaps Group S a 3.37%$ 3.373 millions
Astrazeneca Plc3.29%$ 3.292 millions
West Pharmaceutical Services Inc 3.22%$ 3.217 millions
Dentsply Sirona Inc 2.95%$ 2.950 millions
AnTix Holdings, Inc.2.93%$ 2.926 millions
Oculis Holding Ag2.90%$ 2.899 millions


About Procaps Group S A Revenue Growth Rates (PROCF), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sofgen Pharma S A (CIK 1863362).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-028293
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sofgen Pharma S A’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.